Janice Hitchcock, PhD, has extensive experience in regulatory affairs and drug development, with over 25 years in the pharmaceutical industry. Dr. Hitchcock joined Acumen in 2018 to lead regulatory strategy for ACU193. She was previously at Eli Lilly and Company for 17 years, where she was regulatory affairs director responsible for early- and late-phase drug development programs in Alzheimer’s disease, and represented Lilly regulatory affairs in several public-private collaborations in Alzheimer’s. Dr. Hitchcock received two Lilly Research President’s Awards: one in 2009 for her work in establishing Lilly regulatory recommendations for development of biologics, and the other in 2015 for her leadership role in engagement with external stakeholders on Alzheimer’s regulatory policy. She was also named one of Lilly’s top 100 Innovators in 2013 for her regulatory contributions to the first clinical trial in preclinical Alzheimer’s disease. Dr. Hitchcock received her PhD in Psychology from Yale University. She completed a postdoctoral fellowship at the University of Miami and subsequently headed a behavioral pharmacology research laboratory for 10 years at Hoechst Marion Roussel/Aventis. Dr. Hitchcock is also co-author of several patents.
Rising to New Heights in the Fight Against Alzheimer’s Disease